drugset / Trial / NCT06960928
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
Phase 3
Recruiting
80 enrolled
Icahn School of Medicine at Mount Sinai
PolyBio Research Foundation · collabThe Anlyan Center · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo. This study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.
Timeline
- Start
- 2025-04-18
- Primary completion
- 2026-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 4 mg | — |